| 0.38 0 (0%) | 04-04 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.08 | 1-year : | 0.11 |
| Resists | First : | 0.07 | Second : | 0.1 |
| Pivot price | 0.04 |
|||
| Supports | First : | 0.03 | Second : | 0.02 |
| MAs | MA(5) : | 0.04 |
MA(20) : | 0.05 |
| MA(100) : | 1.31 |
MA(250) : | 11.02 |
|
| MACD | MACD : | -0.1  |
Signal : | -0.1 |
| %K %D | K(14,3) : | 25.1 |
D(3) : | 25.1 |
| RSI | RSI(14): 36.1 |
|||
| 52-week | High : | 52.4 | Low : | 0.03 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ QTNT ] has closed above bottom band by 25.5%. Bollinger Bands are 97.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 70 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.06 - 0.06 | 0.06 - 0.06 |
| Low: | 0.04 - 0.04 | 0.04 - 0.04 |
| Close: | 0.04 - 0.04 | 0.04 - 0.04 |
Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, commercializes, and sells products for the global transfusion diagnostics market in the United States, France, Japan, and internationally. The company is developing MosaiQ, a proprietary technology platform, which provides tests for immunohematology, serological disease screening, and molecular disease screening. Its conventional reagent products for blood grouping include antisera products that are used to identify blood group antigens; reagent red blood cells, which enable the identification of blood group antibodies; whole blood control products for use as daily quality assurance tests; and ancillary products that are used to support blood grouping. The company also offers MosaiQ SDS Microarray that is designed as a serological disease screening microarray comprised assays to detect cytomegalovirus and Syphilis; MosaiQ MDS Microarray that is designed as a molecular disease screening microarray test for donor red cells or source plasma; MosaiQ IH Microarray as a blood grouping microarray; MosaiQ Autoimmune Microarray; MosaiQ COVID-19; and MosaiQ IH3 Microarray. It sells its products to hospitals, donor collection agencies, independent testing laboratories, original equipment manufacturers, and blood banking operation and other diagnostics companies. Quotient Limited was founded in 2007 and is headquartered in Eysins, Switzerland.
Tue, 23 Apr 2024
Zacks.com featured highlights include: SunOpta, Lazydays, Quotient, OptiNose and Motorcar Parts of America - Yahoo Movies UK
Tue, 15 Nov 2022
Nemaura Medical, Inc. (NMRD) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Movies UK
Wed, 26 Oct 2022
Sannova Appoints Jason Apter as CEO and Stephen Unger as CFO - Business Wire
Thu, 10 Jun 2021
10 Best Stocks to Buy According to Highbridge Capital - Yahoo Finance
Mon, 04 Nov 2019
Quotient (QTNT) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Movies Canada
Fri, 13 Sep 2019
58 Biggest Movers From Yesterday - Aurora Cannabis (NASDAQ:ACB), Adverum Biotechnologies (NASDAQ:ADVM) - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | -0.59 |
| EPS Est This Year | -2.01 |
| EPS Est Next Year | -1.3 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0.14 |
| Sales Per Share | 0.37 |
| EBITDA (p.s.) | -0.99 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0.1 |
| Price to Cash Flow | 0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|